MoneyWorks4Me

Epigral informs about outcome of board meeting

27 Jul 2026 Evaluate
Epigral has informed that the Board of Directors of the Company at its meeting held today i.e. Monday, 27th July, 2026 has discussed, approved, and taken on record the following matters: Approved Un-Audited Financial Results (Standalone & Consolidated) of the Company for the First Quarter ended on 30th June, 2026; and took on record ‘Limited Review Report’ thereon issued by S R B C & CO LLP, Statutory Auditors of the Company. A copy of the approved Un-Audited Financial Results along with Limited Review Report are enclosed. The meeting commenced at 12:00 Noon and concluded at 01:45 pm at the Registered Office of the Company situated at Ahmedabad.

The above information is a part of company’s filings submitted to BSE.

Epigral Share Price

1112.60 14.25 (1.30%)
17-Aug-2026 10:55 View Price Chart
Peers
Company Name CMP
SRF 2630.00
BASF India 4047.25
Pidilite Inds. 1680.50
Tata Chemicals 667.50
GNFC 585.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: